The Translational Pulmonary and Immunology Research Center

Progressive research, clinical care and patient advocacy UNITE to advance the treatment of orphan diseases.


The Translational Pulmonary and Immunology Research Center (TPIRC): a rare disease institute, is a nonprofit, tax exempt organization under section 501(c)(3) of the Internal Revenue Code). The primary purpose of TPIRC is to seamlessly integrate AdvocacyClinical Science and Research around specific rare conditions. By joining together FIVE separate conditions, this unique, collaborative approach is amplified across all three areas. The result is faster, more profound and positive outcomes for the following rare diseases:


Food Allergies and Intolerance

Adult Cystic Fibrosis


Airway Inflammatory Disorders


Sick Childen Hope

Rare diseases afflict over 30 million Americans and represent over 7,000 conditions. There is often little or no treatment for these conditions. Rare diseases require clinical expertise by physicians who are few in number nationally. These conditions lack the population numbers to drive advocacy and philanthropy to quickly impact the lives of those affected.




The Translational Pulmonary and Immunology Research Center (TPIRC), a nonprofit organization, will operate as a rare disease institute comprehensively joining basic/translational research, cutting edge clinical care, clinical trials, disease education/awareness and philanthropy under one physical structure in Long Beach, California. Located adjacent to a large children’s and adult medical center, TPIRC offers the unique opportunity to join clinical physician researchers with basic scientists and disease advocates under one roof.




The founding members of TPIRC have agreed to focus the initial mission of the research center on five orphan conditions: Food Allergy and Intolerance, Adult Cystic Fibrosis, Brochiectasis, Immunodeficiency, and Airway Inflammatory Disorders. While these very different conditions all involve immune system mechanisms of disease, the strength of joining these conditions is threefold: First, the patient populations involved in these conditions are locally cared for in the clinical hospital adjacent to TPIRC. Second, the shared costs of the research, clinical and advocacy workforce allow for greater impact on the various rare diseases at a fraction of the cost. Third, the nonprofit, accountability model of TPIRC creates a safe and diverse environment for collaboration with local universities and laboratories which drives research discovery and improved clinical care models.